Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1881-1890 of 2867 for cancer

Edit search filters
  1. A Study To Compare Venetoclax With Fulvestrant Vs. Fulvestrant Alone In Women With Locally Advanced Or Metastatic HER2-negative Cancer Who Have Progressed Or Recurred On A CDK4/6 Inhibitor

    Scottsdale/Phoenix, AZ

  2. Testing A Standardized Approach To Surgery And Chemotherapy For Type I Pleuropulmonary Blastoma Or The Addition Of An Anti-cancer Drug, Topotecan, To The Usual Treatment For Types II And III Pleuropulmonary Blastoma

    Rochester, MN

  3. A Phase 3 Randomized, Placebo-controlled, Double-blind Study Of Niraparib In Combination With Abiraterone Acetate And Prednisone Versus Abiraterone Acetate And Prednisone For Treatment Of Subjects With Metastatic Prostate Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  4. A Study To Assess The Effectiveness, Safety, And Drug/Body Interactions Of Rovalpituzumab For Third-Line And Later Treatment Of Patients With Small Cell Lung Cancer That Has Returned Or Is Resistant To Treatment

    Rochester, MN

  5. Study Of Radium-223 Dichloride Versus Placebo And Hormonal Treatment As Background Therapy In Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

    Rochester, MN

  6. A Study To Find The Recommended Dose For Further Research For VX-970 And Whole Brain Radiation Therapy To Treat Patients With Brain Metastases From Non-Small Cell Lung Cancer

    Jacksonville, FL, Rochester, MN

  7. Study Of Radium-223 Dichloride Versus Placebo And Treatment With Exemestane / Everolimus In Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

    Rochester, MN

  8. Study To Assess Adverse Events And Change In Disease Activity In Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer In Combination With IV Fluorouracil, Folinic Acid, And Bevacizumab

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  9. A Open Label Study Of The Efficacy And Safety Of PD0332991 A Selective Inhibitor Of The Cyclin Dependent Kinases 4 And 6 In Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency And Low P16 Expression

    Rochester, MN

  10. A Study Evaluating Safety And Efficacy Of The Addition Of ABT-888 Plus Carboplatin Versus The Addition Of Carboplatin To Standard Chemotherapy Versus Standard Chemotherapy In Subjects With Early Stage Triple Negative Breast Cancer

    Scottsdale/Phoenix, AZ, Jacksonville, FL

.

Mayo Clinic Footer